Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
KROS

KROS - Keros Therapeutics Inc Stock Price, Fair Value and News

46.44USD+1.03 (+2.27%)Market Closed

Market Summary

KROS
USD46.44+1.03
Market Closed
2.27%

KROS Stock Price

View Fullscreen

KROS RSI Chart

KROS Valuation

Market Cap

1.7B

Price/Earnings (Trailing)

-10.45

Price/Sales (Trailing)

11.8K

EV/EBITDA

-8.11

Price/Free Cashflow

-12.22

KROS Price/Sales (Trailing)

KROS Profitability

EBT Margin

-101319.21%

Return on Equity

-35.31%

Return on Assets

-33%

Free Cashflow Yield

-8.19%

KROS Fundamentals

KROS Revenue

Revenue (TTM)

151.0K

KROS Earnings

Earnings (TTM)

-160.3M

Earnings Growth (Yr)

-20.42%

Earnings Growth (Qtr)

-7.13%

Breaking Down KROS Revenue

Last 7 days

-5.9%

Last 30 days

-9.1%

Last 90 days

-29.5%

Trailing 12 Months

11.9%

How does KROS drawdown profile look like?

KROS Financial Health

Current Ratio

24.74

KROS Investor Care

Shares Dilution (1Y)

21.97%

Diluted EPS (TTM)

-5.15

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20240000
20230000
20220000
2021013.4M16.7M20.1M
201910.0M10.0M10.0M10.0M
201800010.0M

Tracking the Latest Insider Buys and Sells of Keros Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Nov 04, 2023
regnante keith
acquired
640,000
16.00
40,000
chief financial officer
Nov 04, 2023
regnante keith
sold
-1,811,600
45.29
-40,000
chief financial officer
Jun 09, 2023
regnante keith
acquired
320,000
16.00
20,000
chief financial officer
Jun 09, 2023
regnante keith
sold
-908,367
45.4184
-20,000
chief financial officer
Jun 08, 2023
regnante keith
acquired
320,000
16.00
20,000
chief financial officer
Jun 08, 2023
regnante keith
sold
-955,872
47.7936
-20,000
chief financial officer
Apr 08, 2023
seehra jasbir
acquired
1,920
0.48
4,000
chief executive officer
Nov 29, 2022
pontifax management 4 g.p. (2015) ltd.
sold
-0.7176
0.0001
-7,176
-
Nov 29, 2022
nussbaum ran
sold
-0.7176
0.0001
-7,176
-
Nov 29, 2022
kariv tomer
sold
-0.7176
0.0001
-7,176
-

1–10 of 50

Which funds bought or sold KROS recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jun 04, 2024
DekaBank Deutsche Girozentrale
unchanged
-
178,000
488,000
-%
May 29, 2024
Opaleye Management Inc.
added
2.8
10,114,300
24,328,500
5.30%
May 21, 2024
China Universal Asset Management Co., Ltd.
added
99.88
319,839
457,839
0.06%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
added
14.01
792,996
1,675,790
-%
May 16, 2024
JANE STREET GROUP, LLC
reduced
-0.2
510,870
1,282,890
-%
May 15, 2024
Engineers Gate Manager LP
new
-
2,148,790
2,148,790
0.06%
May 15, 2024
Cresset Asset Management, LLC
reduced
-31.34
40,849
326,167
-%
May 15, 2024
TWO SIGMA ADVISERS, LP
new
-
946,660
946,660
-%
May 15, 2024
Voya Investment Management LLC
added
76.22
2,586,540
3,923,870
-%
May 15, 2024
Tower Research Capital LLC (TRC)
reduced
-89.17
-269,248
59,249
-%

1–10 of 45

Are Funds Buying or Selling KROS?

Are funds buying KROS calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own KROS
No. of Funds

Unveiling Keros Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
alkeon capital management llc
5.0%
1,498,907
SC 13G/A
Feb 09, 2024
fmr llc
-
0
SC 13G/A
Jan 26, 2024
blackrock inc.
6.8%
2,036,788
SC 13G/A
Dec 13, 2023
orbimed advisors llc
4.2%
1,268,734
SC 13D/A
Feb 14, 2023
deep track capital, lp
0%
0
SC 13G/A
Feb 13, 2023
alkeon capital management llc
5.1%
1,392,402
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 07, 2023
blackrock inc.
5.9%
1,638,326
SC 13G/A
Feb 02, 2023
arkin moshe
4.98%
1,371,074
SC 13G/A
Nov 07, 2022
orbimed advisors llc
4.6%
1,268,734
SC 13D/A

Recent SEC filings of Keros Therapeutics Inc

View All Filings
Date Filed Form Type Document
Jun 17, 2024
424B5
Prospectus Filed
Jun 17, 2024
8-K
Current Report
Jun 17, 2024
8-K
Current Report
Jun 17, 2024
8-K
Current Report
Jun 05, 2024
3
Insider Trading
Jun 05, 2024
4
Insider Trading
Jun 04, 2024
8-K
Current Report
Jun 03, 2024
4
Insider Trading
Jun 03, 2024
4
Insider Trading
Jun 03, 2024
4
Insider Trading

Peers (Alternatives to Keros Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
51.1B
6.8B
-18.41% 10.61%
-8.56
7.46
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
20.9B
2.0B
9.73% -16.82%
-63.08
10.46
75.20% 68.82%
15.9B
2.5B
9.61% -12.35%
77.45
6.44
13.74% 186.89%
14.2B
3.8B
8.63% 2.12%
19.04
3.77
8.58% 129.81%
MID-CAP
5.1B
107.9M
-6.63% 69.33%
-9.36
48.09
54.84% -28.31%
4.6B
524.1M
-12.71% -56.08%
-11.07
8.81
394.93% 39.61%
3.6B
251.0M
-0.36% -15.32%
-12.26
14.48
73.58% -86.73%
3.2B
240.7M
1.47% -28.24%
-6.7
12.77
-1.03% -213.92%
2.5B
813.8M
-3.10% -36.23%
-1.5K
3.11
56.43% 98.83%
2.0B
996.6M
-10.70% 95.81%
-4.94
1.98
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-3.41% 18.74%
28.28
4.48
60.38% -34.49%
453.7M
881.7K
-5.58% 440.76%
-13.44
481.06
-77.61% 33.36%
209.4M
4.2M
-28.18% 49.63%
-1.68
50.33
-66.30% 48.24%
18.2M
2.1M
-6.22% 224.62%
-0.79
7.61
-13.45% 69.54%

Keros Therapeutics Inc News

Latest updates
Yahoo Lifestyle Australia20 Jun 202412:21 pm
Defense World20 Jun 202411:14 am
MarketBeat19 Jun 202401:48 am
MarketBeat18 Jun 202412:24 am
Nasdaq17 Jun 202408:53 pm
InvestorPlace08 May 202407:00 am

Keros Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q32022Q22021Q42021Q32021Q22019Q42019Q32019Q22019Q12018Q4
Revenue13.2%5,806,0005,130,7504,455,5003,780,2503,105,0003,705,0003,376,0003,157,0002,938,0002,719,0002,500,0002,500,0002,500,0002,500,000-
Operating Expenses4.2%48,566,00046,598,00043,288,00041,337,00038,869,00027,976,00030,728,00024,866,00020,197,00015,641,0005,228,0004,826,0005,151,0005,358,000-
  S&GA Expenses13.2%10,308,0009,105,0009,148,0008,803,0007,778,0006,937,0007,447,0006,033,0005,365,0005,658,0001,067,000972,000654,000491,000-
  R&D Expenses2.0%38,258,00037,493,00034,140,00032,534,00031,091,00021,039,00023,281,00018,833,00014,832,0009,983,0004,161,0003,854,0004,497,0004,867,000-
EBITDA Margin0%-1,007-1,007-29.92-15.30-10.27-5.89-4.54-2.80-3.71-4.03-----
Interest Expenses--------1,0001,0001,000-3,0002,0002,000-
Income Taxes--------1,999,000-38,000------
Earnings Before Taxes-------23,509,000-27,266,000-4,941,000-20,335,000-15,622,000-2,751,000-3,549,000-2,853,000-3,183,000-
EBT Margin0%-1,013-1,013-30.12-15.39-10.34-5.94-4.57-2.82-3.73-4.05-----
Net Income-7.1%-43,114,000-40,243,000-39,440,000-37,505,000-35,804,000-23,509,000-27,266,000-6,940,000-20,297,000-15,622,000-2,751,000-3,549,000-2,853,000-3,183,000-
Net Income Margin-4.8%-1,061-1,013-40.99-18.61-11.49-6.09-4.69-2.92-3.73-4.06-----
Free Cashflow-75.0%-45,506,000-26,000,000-34,532,000-31,143,000-35,297,000-24,778,000-23,157,000-19,724,000-14,586,000-18,147,000-----
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42018Q4
Assets31.3%48637032635638430725322723525523024325826913815061.0011.0027.00
  Current Assets33.4%46334730433436228624622223125122624125626813614959.009.0026.00
    Cash Equivalents33.6%44233128832235128023921622923022123725526613414555.007.0023.00
  Net PPE7.3%4.004.003.003.003.002.002.002.001.001.001.001.001.001.001.001.001.001.001.00
Liabilities-15.7%32.0038.0030.0030.0029.0029.0012.0015.0012.0012.0011.008.009.008.007.009.0010.0010.0015.00
  Current Liabilities-23.2%19.0024.0017.0016.0015.0017.0012.0015.0012.0012.0011.008.009.007.007.008.009.004.0011.00
Shareholder's Equity36.6%454332296326355277241211223243218236248262131141---
  Retained Earnings-11.3%-424-381-341-301-264-228-198-175-147-123-116-96.52-80.90-65.01-54.33-42.30-31.54-19.65-7.31
  Additional Paid-In Capital23.1%8787146376286195064403863713673353323293271851847.000.000.00
Shares Outstanding13.3%36.0032.0030.0030.0028.0028.0026.0024.0024.0023.0023.0023.00-------
Float----905---471---657---386---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-75.0%-44,560-25,459-33,982-30,832-34,235-21,443-24,602-22,590-1,427-19,565-14,441-17,637-10,505-7,991-10,856-9,927-8,120-5,498-2,955-5,032-2,513
  Share Based Compensation10.2%8,0707,3248,7117,0415,6874,7464,7544,7944,3883,2953,0842,8492,4941,5221,4241,13912.0018.0017.0013.0011.00
Cashflow From Investing-74.9%-946-541-550-311-1,062-351-176-567-147-159-145-510-210-60.00-30.00-28.00-176-18.00-82.00-171-
Cashflow From Financing126.4%156,80269,2542841,740107,67861,41648,58310,19211828,41635.0057.0042.00140,1179.00100,12455,7944.006.004.00-
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

KROS Income Statement

2024-03-31
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenues [Abstract]  
Total revenue$ 83$ 0
OPERATING EXPENSES:  
Research and development(38,258)(31,091)
General and administrative(10,308)(7,778)
Total operating expenses(48,566)(38,869)
LOSS FROM OPERATIONS(48,483)(38,869)
OTHER INCOME (EXPENSE), NET  
Dividend income5,8063,105
Other expense, net(437)(40)
Total other income, net5,3693,065
Net loss(43,114)(35,804)
Net loss attributable to common stockholders—basic(43,114)(35,804)
Net loss attributable to common stockholders— diluted$ (43,114)$ (35,804)
Net loss per share attributable to common stockholders - basic (in USD per share)$ (1.21)$ (1.26)
Net loss per share attributable to common stockholders - diluted (in USD per share)$ (1.21)$ (1.26)
Weighted-average common stock outstanding - basic (in shares)35,685,42228,369,453
Weighted-average common stock outstanding - diluted (in shares)35,685,42228,369,453
Revenue, Product and Service [Extensible Enumeration]License revenueLicense revenue
Service and other revenue  
Revenues [Abstract]  
Total revenue$ 83$ 0

KROS Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
CURRENT ASSETS:  
Cash and cash equivalents$ 442,443$ 331,147
Accounts receivable226143
Prepaid expenses and other current assets20,45716,003
Total current assets463,126347,293
Operating lease right-of-use assets14,99515,334
Property and equipment, net4,4344,134
Restricted cash1,2121,212
Other long-term assets2,0522,052
TOTAL ASSETS485,819370,025
CURRENT LIABILITIES:  
Accounts payable4,9865,450
Current portion of operating lease liabilities1,0501,005
Accrued expenses and other current liabilities12,68217,918
Total current liabilities18,71824,373
Operating lease liabilities, net of current portion13,15413,439
Total liabilities31,87237,812
STOCKHOLDERS' EQUITY:  
Preferred stock, par value of $0.0001 per share; $10,000,000 shares authorized as of March 31, 2024 and December 31, 2023, respectively; no shares issued and outstanding00
Common stock, par value of $0.0001 per share; 200,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 36,067,786 and 31,841,084 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively33
Additional paid-in capital878,484713,636
Accumulated deficit(424,540)(381,426)
Total stockholders' equity453,947332,213
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY$ 485,819$ 370,025
KROS
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical need in the United States. The company's lead protein therapeutic product candidate KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-047, a small molecule product candidate that is in Phase II clinical trials for the treatment of functional iron deficiency; and KER-012, which is in Phase II clinical trials to treat pulmonary arterial hypertension and cardiovascular disorders. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
 CEO
 WEBSITEkerostx.com
 INDUSTRYBiotechnology
 EMPLOYEES121

Keros Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for Keros Therapeutics Inc? What does KROS stand for in stocks?

KROS is the stock ticker symbol of Keros Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Keros Therapeutics Inc (KROS)?

As of Fri Jun 21 2024, market cap of Keros Therapeutics Inc is 1.68 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of KROS stock?

You can check KROS's fair value in chart for subscribers.

What is the fair value of KROS stock?

You can check KROS's fair value in chart for subscribers. The fair value of Keros Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Keros Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for KROS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Keros Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether KROS is over valued or under valued. Whether Keros Therapeutics Inc is cheap or expensive depends on the assumptions which impact Keros Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for KROS.

What is Keros Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jun 21 2024, KROS's PE ratio (Price to Earnings) is -10.45 and Price to Sales (PS) ratio is 11.82 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. KROS PE ratio will change depending on the future growth rate expectations of investors.